Dapsone and Sulfasalazine as Adjuvant Therapies in Pemphigus Vulgaris: A Systematic Review
Main Article Content
Keywords
Bullous disorders, Pemphigus, Pemphigus Vulgaris, Adjuvant therapy, Dermatology
Abstract
Background: Adjuvant treatments are often employed in pemphigus vulgaris (PV) to reduce dependence on corticosteroids. When first-line adjuvants are ineffective, considering alternative adjuvant therapies may be necessary. Dapsone and sulfasalazine represent two options.
Objective: To evaluate the use of dapsone and sulfasalazine in the treatment of PV.
Methods: A PubMed search identified patients with PV treated with dapsone or sulfasalazine. We included all studies with ≥3 patients published in English between 1980 and December 2022. Clinical improvement was defined as disease control or complete remission (when adjuvant therapy was initiated in uncontrolled disease) and as a reduction of corticosteroids to ≤7.5 mg per day (when adjuvant therapy was initiated in controlled disease).
Results: Eleven studies were identified representing 75 patients treated with dapsone and 66 patients treated with sulfasalazine. Six patients received dapsone monotherapy, and all had clinical improvement. Sixty-nine received adjuvant dapsone, leading to clinical improvement in 40 (58%). Fifty-seven patients received sulfasalazine as an adjuvant to intravenous corticosteroids, leading to clinical improvement in 49 (86%). The remaining 9 patients received sulfasalazine following rituximab, and all had clinical improvement.
Conclusions: Dapsone and sulfasalazine have evidence supporting their efficacy and can be considered when first-line adjuvant therapies are unsuccessful.
References
2. Schmidt E, Kasperkiewicz M, Joly P.: Pemphigus. Lancet. 2019;394(10201):882-894.
3. Harman KE, Brown D, Exton LS, et al.: British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017. B Jr Dermatol. 2017;177(5):1170-1201.
4. Joly P, Horvath B, Patsatsi A, et al.: Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900-1913.
5. Sarnes E, Crofford L, Watson M, Dennis G, Kan H, Bass D.: Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther. 2011;33(10):1413-1432.
6. Joly P, Horvath B, Patsatsi A, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900-1913.
7. Almugairen N, Hospital V, Bedane C et al.: Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids. J Am Acad Dermatol. 2013;69(4):583-588.
8. A Herbst, JC Brystyn. Patterns of remission in pemphigus vulgaris.: J Am Acad Dermatol. 2000;42(3):422-427.
9. Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al.: First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, muticentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031-2040.
10. Ahmed AR, Shetty S.: A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab. Autoimmun Rev. 2015;14(4):323-331.
11. Sukanjanapong S, Thongtan D, Kanokrungsee S, Suchonwanit P, Chanprapaph K.: A comparison of azathioprine and mycophenolate mofetil as adjuvant drugs in patients with pemphigus: a retrospective cohort study. Dermatol Ther (Heidelb). 2020;10(1):179-189.
12. Winkelmann RK, Roth HL.: Dermatitis herpetiformis with acantholysis or pemphigus with response to sulfonamides: report of two cases. Arch Dermatol. 1960;82:385-390.
13. Murrel DF, Dick S, Ahmed AR, et al.: Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58(6):1043-1046.
14. Pearson RW, O’Donoghue M, Kaplan SJ.: Pemphigus vegetans: its relationship to eosinophilic spongiosis and favorable response to dapsone. Arch Dermatol. 1980;116(1):65-68.
15. Piamphongsant T, Ophaswongse S.: Treatment of pemphigus. Int J Dermatol. 1991;30(2):139-146.
16. Ahmed AR, Hombal S.: Use of cyclophosphamide in azathioprine failures in pemphigus. J Am Acad Dermatol. 1987;17(3):437-442.
17. Heaphy MR, Albrecht J, Werth VP.: Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol. 2005;141(6):699-702.
18. Baum S, Debby A, Gilboa S, Trau H, Barzillai A.: Efficacy of dapsone in the treatment of pemphigus vulgaris: a single-center case study. Dermatology. 2016;232(5):578-585.
19. Alkeraye S, AlZamil LR, Alenazi S.: Dapsone in the management of pemphigus and pemphigoid: rediscovery of its long-lost efficacy. Cureus. 2020;12(6):e8805.
20. Azizi A, Lawaf S.: The management of oral pemphigus vulgaris with systemic corticosteroid and dapsone. J Dent Res Dent Clin Dent Prospects. 2008;2(1):33-37.
21. Werth VP, Fivenson D, Pandya AG, et al.: Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol. 2008;144(1):25-32.
22. El-Darouti M, Marzouk S, Abdel Hay R, et al.: The use of sulfasalazine and pentoxifylline (low-cost antitumor necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: a comparative study. Br J Dermatol. 2009;161(2):313-319.
23. Dogra D, Dogra N, Gupta N, Gupta V.: Sulfasalazine and pentoxifylline, a new adjuvant in young pemphigus patients: A pilot study. Indian J Dermatol Venereol Leprol. 2015;81(6):640-642.
24. Navarro-Navarro I, Jiménez-Gallo D, Villegas-Romero I, Valenzuela-Ubiña S, Linares-Barrios M.: Sulfasalazine treatment for persistent pemphigus vulgaris oral lesions after rituximab treatment. Australas J Dermatol. 2021;62(2):e303-306.
25. Gürcan HM, Ahmed AR. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data.: Am J Clin Dermatol. 2009;10(6):383-396.
26. Khalilzadeh M, Shayan M, Jourian S, Rahimi M, Sheibani M, Dehpour AR.: A comprehensive insight into the anti-inflammatory properties of dapsone. Naunyn Schmiedebergs Arch Pharmacol. 2022;395(12):1509-1523.
27. Mushtaq S, Sarkar R. Sulfasalazine in dermatology: a lesser explored drug with broad therapeutic potential.: Int J Womens Dermatol. 2020;16(3):191-198.
28. Moreno ACL, Santi CG, Gabbi TVB, Aoki V, Hashimoto T, Maruta CW.: IgA pemphigus: case series with emphasis on therapeutic response. J Am Acad Dermatol. 2014;70(1):200-201.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.